微创机器人-B(02252)再涨超10%，机器人行业再迎热度，公司商业化进程稳健推进。 东阳光药(06887)涨近7%，中期毛利14.68亿元，伊非尼酮关键数据亮相美国IPF峰会。 创胜集团-B(06628)拉升逾28%，中期净亏损同比收窄17.9%，TST001研究数据首次亮相ASCO。 金界控股(03918)涨超6%，上半年业绩超出市场预期，花旗称Naga3项目不确定性仍存。 绿色动力环保(01330)涨超7%，上半年归母净利同比增加24.49%，供汽业务成为业绩增长核心引擎。 汇量科技(01860)涨7.9% ，上半年收入同比大增四成，机构看好Mintegral平台飞轮效应持续释放。 赤子城科技(09911)再涨超6%，上半年纯利增近1.2倍，今年集团毛利率有望同比大幅优化。 四环医药(00460)再涨超7%，上半年实现扭亏为盈，AI+医美战略布局进入实质性阶段。 国富量子(00290)再涨6.86%，年内累计涨幅已近1.8倍，公司携手华检医疗推进RWA生态构建。 新意网集团(01686)绩后跌超17%，全年纯利同比增8%至9.79亿港元。 恒生生物科技指数逆市上扬1%；指数成份股中，微创机器人（022 ...

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant intraday surge of over 28%, reaching a price of 4.9 HKD, with a trading volume of 21.44 million HKD. The company reported a 40.6% year-on-year decline in revenue to 2.711 million HKD for the mid-year 2025, while the loss narrowed by 17.9% to approximately 110 million HKD, resulting in a loss per share of 0.27 HKD. The revenue decline was primarily attributed to a reduction in CDMO services [1][2]. Group 1 - Chuangsheng Group-B's mid-year 2025 revenue was 2.711 million HKD, a decrease of 40.6% year-on-year [1] - The company reported a loss of approximately 110 million HKD, which is a 17.9% improvement compared to the previous year [1] - The loss per share for the period was 0.27 HKD [1] Group 2 - Recent breakthroughs in research and clinical trials were highlighted, particularly the TST001 treatment for gastric cancer, which showed a median overall survival (mOS) of 20.4 months in a study involving 82 patients [1] - In a subgroup of 26 patients with high CLDN18.2 expression, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68% [1] - The company is set to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers following regulatory approval [2] Group 3 - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, yielding positive early results [2] - The company has also made early clinical progress with innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]

Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase of 28.27%, reaching HKD 4.9, with a trading volume of HKD 21.44 million, following the announcement of its 2025 interim results which showed a revenue decline of 40.6% year-on-year [1] Financial Performance - The company reported a revenue of HKD 2.711 million for the 2025 interim period, a decrease of 40.6% compared to the previous year [1] - The net loss for the period was approximately HKD 110 million, which represents a 17.9% reduction year-on-year [1] - Earnings per share (EPS) showed a loss of HKD 0.27 [1] Clinical Developments - Chuangsheng Group has made significant breakthroughs in research and clinical trials, particularly with TST001 in combination with PD1/CAPOX for first-line treatment of gastric cancer, achieving a median overall survival (mOS) of 20.4 months among 82 enrolled patients [1] - In a subgroup of 26 patients with high expression of CLDN18.2, the mOS was 21.7 months, with a median progression-free survival (mPFS) of 16.6 months and a confirmed objective response rate (cORR) of 68%, with a median duration of response (mDoR) of 16.5 months [1] Future Clinical Trials - Following recent performance meetings, the company plans to initiate a global Phase III clinical trial for TST001 targeting gastric and gastroesophageal cancers upon receiving regulatory approval [2] - The osteoporosis drug Blosozumab (TST002) has entered Phase II clinical trials in China, showing positive early results [2] - The company is also advancing early clinical progress on innovative ADC and bispecific antibody drugs targeting tumors and autoimmune diseases [2]